Australia's Imricor rises on seeking FDA nod for product expansion in U.S.

Shares of medical device developer Imricor IMR.AX rise 5.2% to A$1.935, set for best day since March 25

Co submits its NorthStar mapping system - an MRI-linked system - to the U.S. Food and Drug Administration for pediatric label expansion

"The submission to expand NorthStar to include use with pediatric patients represents another important step in the company’s U.S. commercialization strategy" - Co

Stock up 26.5% YTD